Atlas Trials

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Clinical trial NCT06601192 · COMPLETED

Trial details

NCT number
NCT06601192
Sponsor
Enanta Pharmaceuticals, Inc
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
RSV InfectionQTc Interval
Start date
2024-07-15
Primary completion
2025-02-02
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.